Antifungal DevelopmentScynexis has full rights to the next-generation antifungal SCY-247, which is in Phase 1 development, and data is expected in the third quarter of 2025.
Commercial OpportunityBrexafemme is an approved drug for vulvovaginal candidiasis, presenting a substantial commercial opportunity due to the unmet need.
Financial StabilityScynexis has sufficient capital to reach milestones with $75M in cash, providing a financial runway into mid-2026.